BMRN Projected Dividend Yield
BioMarin Pharmaceutical Inc ( NASDAQ : BMRN )BioMarin Pharmaceutical is a global biotechnology company that develops and commercializes therapies for people with serious and life-threatening rare diseases and medical conditions. Co.'s commercial products include: Vimizim (elosulfase alpha); Naglazyme (galsulfase); Kuvan (sapropterin dihydrochloride); Palynziq (pegvaliase-pqpz); Brineura (cerliponase alfa); Voxzogo (vosoritide); and Aldurazyme (laronidase). Co.'s clinical development programs include: Valoctocogene roxaparvovec, which is an adeno associated virus (AAV5) vector drug development candidate; BMN 307, which is an AAV5 mediated gene therapy; and BMN 225, which is a small-molecule therapy. 21 YEAR PERFORMANCE RESULTS |
BMRN Dividend History Detail BMRN Dividend News BMRN Competitors News |
Year |
Declaration Date |
Ex-Dividend Date |
Record Date |
Payable Date |
Dividend $ Amount |
Total: |
0.0000 |